Advertisement

From Mouse to Man: N-Methyl-d-Aspartic Acid Receptor Activation as a Promising Pharmacotherapeutic Strategy for Autism Spectrum Disorders

Published:October 27, 2022DOI:https://doi.org/10.1016/j.mcna.2022.05.002

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Medical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Burket J.A.
        • Cannon W.R.
        • Jacome L.F.
        • et al.
        MK-801, a noncompetitive NMDA receptor antagonist, elicits circling behavior in the genetically inbred Balb/c mouse strain.
        Brain Res Bull. 2010; 83: 337-339
        • Deutsch S.I.
        • Mastropaolo J.
        • Riggs R.L.
        • et al.
        The antiseizure efficacies of MK-801, phencyclidine, ketamine, and memantine are altered selectively by stress.
        Pharmacol Biochem Behav. 1997; 58: 709-712
        • Deutsch S.I.
        • Mastropaolo J.
        • Powell D.G.
        • et al.
        Inbred mouse strains differ in their sensitivity to an antiseizure effect of MK-801.
        Clin Neuropharmacol. 1998; 21: 255-257
        • Deutsch S.I.
        • Rosse R.B.
        • Paul S.M.
        • et al.
        Inbred mouse strains differ in sensitivity to “popping” behavior elicited by MK-801.
        Pharmacol Biochem Behav. 1997; 57: 315-317
        • Burket J.A.
        • Herndon A.L.
        • Deutsch S.I.
        Locomotor activity of the genetically inbred Balb/c mouse strain is suppressed by a socially salient stimulus.
        Brain Res Bull. 2010; 83: 255-256
        • Deutsch S.I.
        • Burket J.A.
        • Jacome L.F.
        • et al.
        D-Cycloserine improves the impaired sociability of the Balb/c mouse.
        Brain Res Bull. 2011; 84: 8-11
        • Deutsch S.I.
        • Pepe G.J.
        • Burket J.A.
        • et al.
        D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice.
        Brain Res. 2012; 1439: 96-107
        • Jacome L.F.
        • Burket J.A.
        • Herndon A.L.
        • et al.
        D-serine improves dimensions of the sociability deficit of the genetically-inbred Balb/c mouse strain.
        Brain Res Bull. 2011; 84: 12-16
        • Jacome L.F.
        • Burket J.A.
        • Herndon A.L.
        • et al.
        D-Cycloserine enhances social exploration in the Balb/c mouse.
        Brain Res Bull. 2011; 85: 141-144
        • Burket J.A.
        • Benson A.D.
        • Green T.L.
        • et al.
        Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism.
        Prog Neuropsychopharmacol Biol Psychiatry. 2015; 61: 10-17
        • Burket J.A.
        • Pickle J.C.
        • Rusk A.M.
        • et al.
        Glycine transporter type 1 (GlyT1) inhibition improves conspecific-provoked immobility in BALB/c mice: Analysis of corticosterone response and glucocorticoid gene expression in cortex and hippocampus.
        Prog Neuropsychopharmacol Biol Psychiatry. 2020; 99: 109869
        • Burket J.A.
        • Benson A.D.
        • Tang A.H.
        • et al.
        NMDA receptor activation regulates sociability by its effect on mTOR signaling activity.
        Prog Neuropsychopharmacol Biol Psychiatry. 2015; 60C: 60-65
        • Huang Y.
        • Kang B.N.
        • Tian J.
        • et al.
        The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway.
        J Neurosci. 2007; 27: 449-458
        • Onore C.
        • Yang H.
        • Van de Water J.
        • et al.
        Dynamic Akt/mTOR signaling in children with autism spectrum disorder.
        Front Pediatr. 2017; 5: 43
        • Magdalon J.
        • Sánchez-Sánchez S.M.
        • Griesi-Oliveira K.
        • et al.
        Dysfunctional mTORC1 signaling: a convergent mechanism between syndromic and nonsyndromic forms of autism spectrum disorder?.
        Int J Mol Sci. 2017; 18: E659
        • Ehninger D.
        From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.
        Neuropharmacology. 2013; 68: 97-105
        • Ehninger D.
        • Silva A.J.
        Rapamycin for treating tuberous sclerosis and autism spectrum disorders.
        Trends Mol Med. 2011; 17: 78-87
        • Britto F.A.
        • Dumas K.
        • Giorgetti-Peraldi S.
        • et al.
        Is REDD1 a metabolic double agent? Lessons from physiology and pathology.
        Am J Physiol Cell Physiol. 2020; 319: C807-C824
        • Hansen K.B.
        • Yi F.
        • Perszyk R.E.
        • et al.
        Structure, function, and allosteric modulation of NMDA receptors.
        J Gen Physiol. 2018; 150: 1081-1105
        • Traynelis S.F.
        • Wollmuth L.P.
        • McBain C.J.
        • et al.
        Glutamate receptor ion channels: structure, regulation, and function.
        Pharmacol Rev. 2010; 62: 405-496
        • Nisar S.
        • Bhat A.A.
        • Masoodi T.
        • et al.
        Genetics of glutamate and its receptors in autism spectrum disorder.
        Mol Psychiatry. 2022; (Published online March 16)https://doi.org/10.1038/s41380-022-01506-w
        • Deutsch S.I.
        • Luyo Z.N.M.
        • Burket J.A.
        Targeted NMDA receptor interventions for autism: developmentally determined expression of GluN2B and GluN2A-containing receptors and balanced allosteric modulatory approaches.
        Biomolecules. 2022; 12: 181
        • Hansen K.B.
        • Furukawa H.
        • Traynelis S.F.
        Control of assembly and function of glutamate receptors by the amino-terminal domain.
        Mol Pharmacol. 2010; 78: 535-549
        • Burket J.A.
        • Deutsch S.I.
        Metabotropic functions of the NMDA receptor and an evolving rationale for exploring NR2A-selective positive allosteric modulators for the treatment of autism spectrum disorder.
        Prog Neuropsychopharmacol Biol Psychiatry. 2019; 90: 142-160
        • Hardingham G.E.
        NMDA receptor C-terminal signaling in development, plasticity, and disease.
        F1000Res. 2019; 8 (Faculty Rev-1547): F1000
        • Liu S.
        • Zhou L.
        • Yuan H.
        • et al.
        A rare variant identified within the GluN2B C-terminus in a patient with autism affects NMDA receptor surface expression and spine density.
        J Neurosci. 2017; 37: 4093-4102
        • Wyllie D.J.A.
        • Livesey M.R.
        • Hardingham G.E.
        Influence of GluN2 subunit identity on NMDA receptor function.
        Neuropharmacology. 2013; 74: 4-17
        • Herbrechter R.
        • Hube N.
        • Buchholz R.
        • et al.
        Splicing and editing of ionotropic glutamate receptors: a comprehensive analysis based on human RNA-seq data.
        Cell Mol Life Sci. 2021; 78: 5605-5630
        • Vieira M.
        • Yong X.L.H.
        • Roche K.W.
        • et al.
        Regulation of NMDA glutamate receptor functions by the GluN2 subunits.
        J Neurochem. 2020; 154: 121-143
        • Vizi E.S.
        • Kisfali M.
        • Lőrincz T.
        Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: Evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects.
        Brain Res Bull. 2013; 93: 32-38
        • Shipton O.A.
        • Paulsen O.
        GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity.
        Philos Trans R Soc Lond B Biol Sci. 2014; 369: 20130163
        • Monyer H.
        • Burnashev N.
        • Laurie D.J.
        • et al.
        Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
        Neuron. 1994; 12: 529-540
        • Sapkota K.
        • Dore K.
        • Tang K.
        • et al.
        The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators.
        Biochem Pharmacol. 2019; 159: 140
        • Choi Y.B.
        • Tenneti L.
        • Le D.A.
        • et al.
        Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation.
        Nat Neurosci. 2000; 3: 15-21
        • Burket J.A.
        • Webb J.D.
        • Deutsch S.I.
        Perineuronal nets and metal cation concentrations in the microenvironments of fast-spiking, parvalbumin-expressing GABAergic interneurons: relevance to neurodevelopment and neurodevelopmental disorders.
        Biomolecules. 2021; 11: 1235
        • Awad H.
        • Hubert G.W.
        • Smith Y.
        • et al.
        Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.
        J Neurosci. 2000; 20: 7871-7879
        • Gu L.
        • Luo W.Y.
        • Xia N.
        • et al.
        Upregulated mGluR5 induces ER stress and DNA damage by regulating the NMDA receptor subunit NR2B.
        J Biochem. 2022; 171: 349-359
        • Takagi N.
        • Besshoh S.
        • Morita H.
        • et al.
        Metabotropic glutamate mGlu5 receptor-mediated serine phosphorylation of NMDA receptor subunit NR1 in hippocampal CA1 region after transient global ischemia in rats.
        Eur J Pharmacol. 2010; 644: 96-100
        • Conn P.J.
        • Lindsley C.W.
        • Jones C.K.
        Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
        Trends Pharmacol Sci. 2009; 30: 25-31
        • Choe E.S.
        • Shin E.H.
        • Wang J.Q.
        Regulation of phosphorylation of NMDA receptor NR1 subunits in the rat neostriatum by group I metabotropic glutamate receptors in vivo.
        Neurosci Lett. 2006; 394: 246-251
        • Clarke R.J.
        • Johnson J.W.
        Voltage-dependent gating of NR1/2B NMDA receptors.
        J Physiol. 2008; 586: 5727-5741
        • Millan M.J.
        N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
        Psychopharmacology (Berl). 2005; 179: 30-53
        • Deutsch S.I.
        • Burket J.A.
        • Benson A.D.
        • et al.
        NMDA agonists for autism spectrum disorders: progress and possibilities.
        Future Neurol. 2015; 10: 485-500
        • Zappettini S.
        • Grilli M.
        • Olivero G.
        • et al.
        Nicotinic α7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens.
        Front Cell Neurosci. 2014; 8 (Available at:) (Accessed March 27, 2022)
        • Yang Y.
        • Paspalas C.D.
        • Jin L.E.
        • et al.
        Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex.
        Proc Natl Acad Sci USA. 2013; 110: 12078-12083
        • Oliet S.H.R.
        • Mothet J.P.
        Regulation of N-methyl-D-aspartate receptors by astrocytic D-serine.
        Neuroscience. 2009; 158: 275-283
        • Dore K.
        • Stein I.S.
        • Brock J.A.
        • et al.
        Unconventional NMDA receptor signaling.
        J Neurosci. 2017; 37: 10800-10807
        • Conn P.J.
        • Christopoulos A.
        • Lindsley C.W.
        Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.
        Nat Rev Drug Discov. 2009; 8: 41-54
        • Geoffroy C.
        • Paoletti P.
        • Mony L.
        Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential.
        J Physiol. 2021; https://doi.org/10.1113/JP280875
        • Hackos D.H.
        • Hanson J.E.
        Diverse modes of NMDA receptor positive allosteric modulation: mechanisms and consequences.
        Neuropharmacology. 2017; 112: 34-45
        • Silverman J.L.
        • Smith D.G.
        • Rizzo S.J.S.
        • et al.
        Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism.
        Sci Transl Med. 2012; 4: 131ra51
        • Labrie V.
        • Wang W.
        • Barger S.W.
        • et al.
        Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.
        Genes Brain Behav. 2010; 9: 11-25
        • Deutsch S.I.
        • Mastropaolo J.
        • Schwartz B.L.
        • et al.
        A “glutamatergic hypothesis” of schizophrenia. Rationale for pharmacotherapy with glycine.
        Clin Neuropharmacol. 1989; 12: 1-13
        • Halene T.B.
        • Ehrlichman R.S.
        • Liang Y.
        • et al.
        Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia.
        Genes Brain Behav. 2009; 8: 661-675
        • Deutsch S.I.
        • Hitri A.
        Measurement of an explosive behavior in the mouse, induced by MK-801, a PCP analogue.
        Clin Neuropharmacol. 1993; 16: 251-257
        • Deutsch S.I.
        • Rosse R.B.
        • Billingslea E.N.
        • et al.
        Topiramate antagonizes MK-801 in an animal model of schizophrenia.
        Eur J Pharmacol. 2002; 449: 121-125
        • Morales M.
        • Spear L.P.
        The effects of an acute challenge with the NMDA receptor antagonists, MK-801, PEAQX, and ifenprodil, on social inhibition in adolescent and adult male rats.
        Psychopharmacology (Berl). 2014; 231: 1797-1807
        • Vishnoi S.
        • Raisuddin S.
        • Parvez S.
        Modulatory effects of an NMDAR partial agonist in MK-801-induced memory impairment.
        Neuroscience. 2015; 311: 22-33
        • Jacome L.F.
        • Burket J.A.
        • Herndon A.L.
        • et al.
        Genetically inbred Balb/c mice differ from outbred Swiss Webster mice on discrete measures of sociability: relevance to a genetic mouse model of autism spectrum disorders.
        Autism Res. 2011; 4: 393-400
        • Rosse R.B.
        • Mastropaolo J.
        • Sussman D.M.
        • et al.
        Computerized measurement of MK-801-elicited popping and hyperactivity in mice.
        Clin Neuropharmacol. 1995; 18: 448-457
        • Deutsch S.I.
        • Rosse R.B.
        • Mastropaolo J.
        Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice.
        Clin Neuropharmacol. 1997; 20: 375-384
        • Brodkin E.S.
        • Goforth S.A.
        • Keene A.H.
        • et al.
        Identification of quantitative trait Loci that affect aggressive behavior in mice.
        J Neurosci. 2002; 22: 1165-1170
        • Bhalala O.G.
        • Nath A.P.
        • Consortium U.B.E.
        • et al.
        Identification of expression quantitative trait loci associated with schizophrenia and affective disorders in normal brain tissue.
        PLOS Genet. 2018; 14: e1007607
        • Perera P.Y.
        • Lichy J.H.
        • Mastropaolo J.
        • et al.
        Expression of NR1, NR2A and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioral sensitivity to MK-801, a noncompetitive NMDA receptor antagonist.
        Eur Neuropsychopharmacol. 2008; 18: 814-819
        • Long K.D.
        • Mastropaolo J.
        • Rosse R.B.
        • et al.
        Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain.
        Brain Res Bull. 2006; 69: 626-630
        • Brodkin E.S.
        BALB/c mice: low sociability and other phenotypes that may be relevant to autism.
        Behav Brain Res. 2007; 176: 53-65
        • Sankoorikal G.M.V.
        • Kaercher K.A.
        • Boon C.J.
        • et al.
        A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains.
        Biol Psychiatry. 2006; 59: 415-423
        • Benson A.D.
        • Burket J.A.
        • Deutsch S.I.
        Balb/c mice treated with D-cycloserine arouse increased social interest in conspecifics.
        Brain Res Bull. 2013; 99: 95-99
        • Green T.L.
        • Burket J.A.
        • Deutsch S.I.
        Age-dependent effects on social interaction of NMDA GluN2A receptor subtype-selective antagonism.
        Brain Res Bull. 2016; 125: 159-167
        • Posey D.J.
        • Kem D.L.
        • Swiezy N.B.
        • et al.
        A pilot study of D-cycloserine in subjects with autistic disorder.
        Am J Psychiatry. 2004; 161: 2115-2117
        • Burket J.A.
        • Benson A.D.
        • Tang A.H.
        • et al.
        D-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling.
        Brain Res Bull. 2013; 96: 62-70
        • Difede J.
        • Cukor J.
        • Wyka K.
        • et al.
        D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.
        Neuropsychopharmacology. 2014; 39: 1052-1058
        • Urbano M.R.
        • Okwara L.
        • Manser P.
        • et al.
        A Trial of D-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders.
        J Neuropsychiatry Clin Neurosci. 2015; 27 (Published online April 2015): 133-138
        • Urbano M.
        • Okwara L.
        • Manser P.
        • et al.
        A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.
        Clin Neuropharmacol. 2014; 37: 69-72
        • de Kleine R.A.
        • Hendriks G.J.
        • Smits J.A.J.
        • et al.
        Prescriptive variables for d-cycloserine augmentation of exposure therapy for posttraumatic stress disorder.
        J Psychiatr Res. 2014; 48: 40-46
        • Goff D.C.
        • Cather C.
        • Gottlieb J.D.
        • et al.
        Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
        Schizophr Res. 2008; 106: 320-327
        • Schade S.
        • Paulus W.
        D-cycloserine in neuropsychiatric diseases: a systematic review.
        Int J Neuropsychopharmacol. 2016; 19: pyv102
        • Crino P.B.
        mTOR: a pathogenic signaling pathway in developmental brain malformations.
        Trends Mol Med. 2011; 17: 734-742
        • Crino P.B.
        The mTOR signalling cascade: paving new roads to cure neurological disease.
        Nat Rev Neurol. 2016; 12: 379-392
        • García-Peñas J.J.
        • Carreras-Sááez I.
        [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].
        Rev Neurol. 2013; 56: S153-S161
        • Laplante M.
        • Sabatini D.M.
        mTOR signaling in growth control and disease.
        Cell. 2012; 149: 274-293
        • Lipton J.O.
        • Sahin M.
        The neurology of mTOR.
        Neuron. 2014; 84: 275-291
        • McCabe M.P.
        • Cullen E.R.
        • Barrows C.M.
        • et al.
        Genetic inactivation of mTORC1 or mTORC2 in neurons reveals distinct functions in glutamatergic synaptic transmission.
        eLife. 2020; 9: e51440
        • Fasolo A.
        • Sessa C.
        Current and future directions in mammalian target of rapamycin inhibitors development.
        Expert Opin Investig Drugs. 2011; 20: 381-394
        • Albert S.
        • Serova M.
        • Dreyer C.
        • et al.
        New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
        Expert Opin Investig Drugs. 2010; 19: 919-930
        • Sahin M.
        Targeted treatment trials for tuberous sclerosis and autism: no longer a dream.
        Curr Opin Neurobiol. 2012; 22: 895-901
        • Tsai P.T.
        • Hull C.
        • Chu Y.
        • et al.
        Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice.
        Nature. 2012; 488: 647-651
        • Tsai V.
        • Parker W.E.
        • Orlova K.A.
        • et al.
        Fetal brain mTOR signaling activation in tuberous sclerosis complex.
        Cereb Cortex. 2014; 24: 315-327
        • Winden K.D.
        • Ebrahimi-Fakhari D.
        • Sahin M.
        Abnormal mTOR Activation in Autism.
        Annu Rev Neurosci. 2018; 41: 1-23
        • Fitzpatrick C.J.
        • Lombroso P.J.
        The role of striatal-enriched protein tyrosine phosphatase (STEP) in cognition.
        Front Neuroanat. 2011; 5: 47
        • Paul S.
        • Connor J.A.
        NR2B-NMDA receptor-mediated increases in intracellular Ca2+ concentration regulate the tyrosine phosphatase, STEP, and ERK MAP kinase signaling.
        J Neurochem. 2010; 114: 1107-1118
        • Paul S.
        • Nairn A.C.
        • Wang P.
        • et al.
        NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling.
        Nat Neurosci. 2003; 6: 34-42
        • Zhang Y.
        • Venkitaramani D.V.
        • Gladding C.M.
        • et al.
        The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation.
        J Neurosci. 2008; 28: 10561-10566
        • Burket J.A.
        • Benson A.D.
        • Tang A.H.
        • et al.
        Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders.
        Brain Res Bull. 2014; 100: 70-75